Imunon reports positive Phase 2 OS data for IMNN-001; net loss narrows in Q2 2024

Imunon, Inc.

2024-Q2 EPS reported -$1.03

Q2 net loss of $4.8M ($0.51/share) vs $5.6M ($0.61/share) in Q2 2023; operating expenses down 8%.
Positive OVATION 2 topline: 11.1-month median OS improvement (HR=0.74) in ITT; 15.7-month gain in per-protocol (HR=0.64).
Phase 3 study of IMNN-001 planned to start Q1 2025 after End-of-Phase 2 FDA meeting.
Raised $10M gross ($9M net) in July 2024 registered direct offering; cash + investments $5.3M at June 30, funding into Q3 2025.
IMNN-101 Phase 1 COVID booster trial enrolling; topline data expected by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.